Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

5.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.4K
Clinical Trials01:16

Clinical Trials

11.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.1K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.6K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.6K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

322
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
322
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

502
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
502

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Imaging Efficacy of [<sup>18</sup>F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same author

Imaging Efficacy of [<sup>18</sup>F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same author

Quantitative <sup>68</sup>Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following <sup>177</sup>Lu-PSMA-617 (VISION Trial).

Radiology·2024
Same author

A VISION Substudy of Reader Agreement on <sup>68</sup>Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for <sup>177</sup>Lu-PSMA-617 Radioligand Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2023
Same author

APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression.

Science translational medicine·2022
Same author

TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.

Neuron·2022

Related Experiment Video

Updated: Mar 21, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K

Tau: From research to clinical development.

David M Holtzman1, Maria C Carrillo2, James A Hendrix2

  • 1Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|May 8, 2016
PubMed
Summary
This summary is machine-generated.

Tau pathology drives Alzheimer's disease progression, making it a key target for new treatments. Advances in preclinical models and biomarkers offer opportunities to understand tau biology and accelerate therapeutic development.

Keywords:
Alzheimer's diseaseBiomarkersNeurofibrillary tanglesTauTauopathies

More Related Videos

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
10:20

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

12.0K
Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
07:45

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

871

Related Experiment Videos

Last Updated: Mar 21, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K
Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
10:20

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

12.0K
Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
07:45

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

871

Area of Science:

  • Neuroscience
  • Neurology
  • Biomedical Research

Background:

  • Tau pathology is a primary driver of Alzheimer's disease (AD) and other neurodegenerative conditions.
  • Understanding tau's role is crucial for developing effective diagnostics and therapeutics.
  • Current knowledge of tau-related neurotoxicity mechanisms remains incomplete.

Purpose of the Study:

  • To discuss the latest advancements in understanding tau pathogenic pathways.
  • To review the development of tau therapeutics and biomarkers.
  • To identify strategies for accelerating tau research from bench to bedside.

Main Methods:

  • Convened a Research Roundtable with experts from academia, industry, and regulatory agencies.
  • Discussed current understanding of tau biology and disease mechanisms.
  • Reviewed emerging tau PET imaging and fluid biomarkers.

Main Results:

  • Highlighted the importance of tau as a therapeutic target in neurodegenerative diseases.
  • Identified progress in preclinical models and biomarker development.
  • Recognized the need for improved understanding of tau neurotoxicity.

Conclusions:

  • Tau-based diagnostics and therapeutics hold significant promise for Alzheimer's disease.
  • Advancements in tau research are crucial for overcoming translational challenges.
  • Collaborative efforts are essential to expedite the development and clinical implementation of tau-targeting strategies.